Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025
On November 17, 2025, Annovis Bio, Inc. (NYSE: ANVS) released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant subset of patients.Annovis Bio+1 The update triggered a sharp rally in ANVS stock and put fresh attention on the company’s multi-disease neurodegeneration strategy. What Annovis Bio Announced Today Annovis Bio’s news centers on a deeper analysis of its Phase 3 study in early Parkinson’s disease, registered as NCT05357989.Annovis Bio+1 According to the company, buntanetap: In this subgroup with amyloid co‑pathology, patients were found to decline faster
